Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization - 26/08/11
Doi : 10.1016/j.amjcard.2004.01.071
Lawrence Liao, MD a, ⁎ 
, Christopher H Cabell, MD a, James G Jollis, MD a, Eric J Velazquez, MD a, William T Smith, MD a, Kevin J Anstrom, PhD a, Paul A Pappas, MS a, Thomas Ryan, MD a, Joseph A Kisslo, MD a, Carolyn K Landolfo, MD b
, Christopher H Cabell, MD a, James G Jollis, MD a, Eric J Velazquez, MD a, William T Smith, MD a, Kevin J Anstrom, PhD a, Paul A Pappas, MS a, Thomas Ryan, MD a, Joseph A Kisslo, MD a, Carolyn K Landolfo, MD b a Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
b Department of Medicine, Division of Cardiology, Medical College of Georgia, Augusta, Georgia, USA
*Dr. Liao's address is: Box 3850, Duke University Medical Center, Durham, North Carolina 27710, USA.
Abstract |
In 107 patients with coronary disease and severe left ventricular dysfunction, we examined the prognostic power of viability identified by dobutamine stress echocardiography. At a mean follow-up of 27 months, patients with viable myocardium who underwent revascularization had a significant survival advantage over all other patients (2-year survival 83.5% vs 57.2%, p = 0.0037).
Le texte complet de cet article est disponible en PDF.© 2004
Excerpta Medica Inc. Tous droits réservés.
Vol 93 - N° 10
P. 1275-1279 - mai 2004 Retour au numéro
Article précédent
- Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients
- Evelyn Regar, Pedro A Lemos, Francesco Saia, Muzaffer Degertekin, Kengo Tanabe, Chi-Hang Lee, Chourmouzios A Arampatzis, Angela Hoye, Georgios Sianos, Pim de Feyter, Willem J van der Giessen, Peter C Smits, Ron T van Domburg, Patrick W Serruys
- Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study)
- Jorge F Saucedo, Luis Garza, David C Wolford, Stephen L Cook, Kodangudi B Ramanathan, Zakaria Matin, Frank A McGrew, Mary V Jacoski, Lisa K Jennings, Tennessee–Arkansas–Mississippi (TAM) Clinical Research Consortium
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?